Published in:
Open Access
01-12-2020 | Supraventricular Tachycardia | Research article
Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience
Authors:
Guangzhi Chen, Yan Wang, Riccardo Proietti, Xunzhang Wang, Feifan Ouyang, Chang Sheng Ma, Rong Hui Yu, Chunxia Zhao, Kezhong Ma, Jie Qiu, Qigong Liu, Dao Wen Wang
Published in:
BMC Cardiovascular Disorders
|
Issue 1/2020
Login to get access
Abstract
Background
Three-dimensional electroanatomic mapping systems have demonstrated a significant reduction in radiation exposure during radiofrequency catheter ablation procedures. We aimed to investigate the safety, feasibility and efficacy of a completely zero-fluoroscopy approach for catheter ablation of supraventricular tachycardia using the Ensite NavX navigation system compared with a conventional fluoroscopy approach.
Methods
A multicenter prospective non-randomized registry study was performed in seven centers from January 2013 to February 2018. Consecutive patients referred for catheter ablation of supraventricular tachycardia were assigned either to a completely zero-fluoroscopic approach (ZF) or conventional fluoroscopy approach (CF) according to the operator’s preference. Patients with atrial tachycardia were excluded.
Results
Totally, 1020 patients were enrolled in ZF group; 2040 patients ablated by CF approach were selected for controls. There was no significant difference between the zero-fluoroscopy group and conventional fluoroscopy group as to procedure time (60.3 ± 20.3 vs. 59.7 ± 22.6 min, P = 0.90), immediate success rate of procedure (98.8% vs. 99.2%, P = 0.22), arrhythmia recurrence (0.4% vs. 0.5%, P = 0.85), total success rate of procedure (98.4% vs. 98.8%, P = 0.39) or complications (1.1% vs. 1.5%, P = 0.41). Compared with the conventional fluoroscopy approach, the zero-fluoroscopy approach provided similar outcomes without compromising the safety or efficacy of the procedure.
Conclusion
The completely zero-fluoroscopy approach demonstrated safety and efficacy comparable to a conventional fluoroscopy approach for catheter ablation of supraventricular tachycardia, and mitigated radiation exposure to both patients and operators.
Trial registration
clinicaltrials.gov Identifier:
NCT03042078; first registered February 3, 2017; retrospectively registered.